These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31704813)

  • 21. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
    Abt D; Besse A; Sedlarikova L; Kraus M; Bader J; Silzle T; Vodinska M; Slaby O; Schmid HP; Engeler DS; Driessen C; Besse L
    BJU Int; 2018 Apr; 121(4):600-609. PubMed ID: 29161753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of lopinavir/ritonavir and lopinavir/ritonavir loaded PLGA nanoparticles on experimental toxoplasmosis.
    Abou-El-Naga IF; El Kerdany ED; Mady RF; Shalaby TI; Zaytoun EM
    Parasitol Int; 2017 Dec; 66(6):735-747. PubMed ID: 28838776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lopinavir-Ritonavir: a new protease inhibitor.
    Mangum EM; Graham KK
    Pharmacotherapy; 2001 Nov; 21(11):1352-63. PubMed ID: 11714208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.
    Gills JJ; Lopiccolo J; Tsurutani J; Shoemaker RH; Best CJ; Abu-Asab MS; Borojerdi J; Warfel NA; Gardner ER; Danish M; Hollander MC; Kawabata S; Tsokos M; Figg WD; Steeg PS; Dennis PA
    Clin Cancer Res; 2007 Sep; 13(17):5183-94. PubMed ID: 17785575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 4-HPR Is an Endoplasmic Reticulum Stress Aggravator and Sensitizes Breast Cancer Cells Resistant to TRAIL/Apo2L.
    Anding AL; Jones JD; Newton MA; Curley RW; Clagett-Dame M
    Anticancer Res; 2018 Aug; 38(8):4403-4416. PubMed ID: 30061204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of NO-Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir.
    Fagone P; Mangano K; Quattrocchi C; Cavalli E; Mammana S; Lombardo GA; Pennisi V; Zocca MB; He M; Al-Abed Y; Nicoletti F
    Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):306-15. PubMed ID: 25903922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium.
    Israr M; Mitchell D; Alam S; Dinello D; Kishel JJ; Meyers C
    HIV Med; 2011 Mar; 12(3):145-56. PubMed ID: 20722750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Corosolic acid, a natural triterpenoid, induces ER stress-dependent apoptosis in human castration resistant prostate cancer cells via activation of IRE-1/JNK, PERK/CHOP and TRIB3.
    Ma B; Zhang H; Wang Y; Zhao A; Zhu Z; Bao X; Sun Y; Li L; Zhang Q
    J Exp Clin Cancer Res; 2018 Sep; 37(1):210. PubMed ID: 30176898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.
    Capel E; Auclair M; Caron-Debarle M; Capeau J
    Antivir Ther; 2012; 17(3):549-56. PubMed ID: 22293506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
    Noor MA; Flint OP; Maa JF; Parker RA
    AIDS; 2006 Sep; 20(14):1813-21. PubMed ID: 16954722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV protease inhibitor Lopinavir induces apoptosis of primary effusion lymphoma cells via suppression of NF-κB pathway.
    Kariya R; Taura M; Suzu S; Kai H; Katano H; Okada S
    Cancer Lett; 2014 Jan; 342(1):52-9. PubMed ID: 24012878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
    J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of initial antiretroviral therapy based on lopinavir/ritonavir plus 2 nucleoside/nucleotide analogs in patients with human immunodeficiency virus type 1 infection].
    Zamora L; Gatell JM
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():2-6. PubMed ID: 25542868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
    Kiser JJ; Carten ML; Aquilante CL; Anderson PL; Wolfe P; King TM; Delahunty T; Bushman LR; Fletcher CV
    Clin Pharmacol Ther; 2008 Feb; 83(2):265-72. PubMed ID: 17597712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer.
    Srirangam A; Mitra R; Wang M; Gorski JC; Badve S; Baldridge L; Hamilton J; Kishimoto H; Hawes J; Li L; Orschell CM; Srour EF; Blum JS; Donner D; Sledge GW; Nakshatri H; Potter DA
    Clin Cancer Res; 2006 Mar; 12(6):1883-96. PubMed ID: 16551874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclopamine sensitizes TRAIL-resistant gastric cancer cells to TRAIL-induced apoptosis via endoplasmic reticulum stress-mediated increase of death receptor 5 and survivin degradation.
    Na YJ; Lee DH; Kim JL; Kim BR; Park SH; Jo MJ; Jeong S; Kim HJ; Lee SY; Jeong YA; Oh SC
    Int J Biochem Cell Biol; 2017 Aug; 89():147-156. PubMed ID: 28624529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo.
    Paskas S; Mazzon E; Basile MS; Cavalli E; Al-Abed Y; He M; Rakocevic S; Nicoletti F; Mijatovic S; Maksimovic-Ivanic D
    Invest New Drugs; 2019 Oct; 37(5):1014-1028. PubMed ID: 30706336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The metabolic effects of lopinavir/ritonavir in HIV-negative men.
    Lee GA; Seneviratne T; Noor MA; Lo JC; Schwarz JM; Aweeka FT; Mulligan K; Schambelan M; Grunfeld C
    AIDS; 2004 Mar; 18(4):641-9. PubMed ID: 15090769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human colon cancer cells.
    Liu J; Edagawa M; Goshima H; Inoue M; Yagita H; Liu Z; Kitajima S
    Biochem Biophys Res Commun; 2014 Mar; 445(2):320-6. PubMed ID: 24530917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.